1. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
- Author
-
Watari R, Sawada H, Hashimoto H, Kasai Y, Oka R, Shimizu R, and Matsuzaki T
- Subjects
- Humans, ATP Binding Cassette Transporter, Subfamily G, Member 2, SARS-CoV-2, Protease Inhibitors, Coproporphyrins metabolism, Coproporphyrins pharmacology, Liver-Specific Organic Anion Transporter 1 metabolism, Neoplasm Proteins metabolism, Enzyme Inhibitors, Antiviral Agents pharmacology, Drug Interactions, COVID-19, Anti-Infective Agents, Indazoles, Triazines, Triazoles
- Abstract
Coproporphyrin-I (CP-I) has been investigated as an endogenous biomarker of organic anion transporting polypeptide (OATP) 1B. Here, we determined the CP-I concentrations in a cocktail drug-drug interaction (DDI) study of ensitrelvir to evaluate the OATP1B inhibitory potential because ensitrelvir had increased plasma concentrations of rosuvastatin in this study, raising concerns about breast cancer resistance protein and OATP1B inhibition. Furthermore, CP-I concentrations were compared between active and placebo groups in a first-in-human (FIH) study of ensitrelvir to verify whether the OATP1B inhibitory potential could be estimated at an early drug development stage. In the cocktail DDI study, CP-I did not differ between with/without administration of ensitrelvir, indicating that ensitrelvir has no OATP1B inhibitory effect. Although there were some individual variabilities in CP-I concentrations among the treatment groups in the FIH study, the normalization of CP-I concentrations with pre-dose values minimized these variabilities, suggesting that this normalized method would be helpful for comparing the CP-I from different participants. Finally, we concluded that CP-I concentrations were not affected by ensitrelvir in the FIH study. These results suggested that the CP-I determination in an FIH study and its normalized method can be useful for an early evaluation of the OATP1B-mediated DDI potential in humans., Competing Interests: Declaration of Competing Interest Financial support for the present study was provided by Shionogi & Co., Ltd. All authors are employees of the SHIONOGI Group (Shionogi & Co., Ltd. and Shionogi TechnoAdvance Research & Co., Ltd.)., (Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF